![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Friday, February 17, 2017 11:54:04 PM
human tissue and human tissue-based research solutions supporting drug
discovery and development, announced today a partnership with
MolecularMD to combine MolecularMD’s expertise as a provider of
molecular diagnostics products and services with Asterand Bio’s drug
target and candidate validation capabilities. MolecularMD is a molecular
diagnostics company that develops custom clinical trial assays as well
as companion diagnostic products, supporting clinical trial services and
commercialization of targeted cancer therapies. The partnership creates
an end-to-end workflow for biopharma clients and strengthens the
companies’ current offerings in assay development & validation, while
creating a global footprint for the efficient delivery of clinical trial
sample analyses.
“For over 20 years, Asterand Bioscience’s experienced scientists have
worked collaboratively with clients to expedite the highest likelihood
for clinical success by providing a variety of pre-clinical
research services,” said John Canepa, Chief Financial Officer/Chief
Operations Officer. “This agreement brings together MolecularMD’s proven
track record in clinical assay development and companion diagnostics
with Asterand Bio’s human tissue procurement, characterization and
research services to provide a comprehensive approach to meet the needs
of pharmaceutical, biotechnology and diagnostic companies from
validation of biomarkers and targets to assay development, through
regulatory and clinical trials.”
“MolecularMD is uniquely suited to assist biopharma clients with our
clinical trial and regulatory expertise,” said Dan Snyder,
President/Chief Executive Officer, MolecularMD. “I’m excited that
Asterand Bio and MolecularMD have joined forces to provide these unique
advantages which will help our broad client base accelerate their
pipeline decisions and dramatically improve the efficiency of the
clinical trial and commercialization workflow.”
Asterand Bio and MolecularMD will both attend Molecular Med Tri-Con
2017, Feb 19-24 at the Moscone North Convention Center, San Francisco,
CA, a meeting bringing together over 3,500 drug discovery and
development professionals. More information about the partnership can be
found at Asterand Bio’s booth #626. Asterand Bio and MolecularMD will
both attend the AACR 2017 meeting, April 1-5 at the Walter E. Washington
Convention Center in Washington DC, a meeting that highlights the
highest level of cancer science and medicine from institutions all over
the world. More information about the partnership can be found at
Asterand Bio’s booth #1340 and MolecularMD’s booth #3423.
About Asterand Bioscience
Asterand Bioscience is the leading global provider of high quality,
well-characterized human tissue and human tissue-based research
solutions to drug discovery scientists. Our mission is to provide
human-based solutions to accelerate the identification and validation of
drug targets and enhance the selection of drug candidates with increased
likelihood of clinical success. From our offices in Detroit, MI and
Royston, U.K. our employees are focused on providing services and
products to accelerate drug discovery research from target
identification through to compound evaluation and drug safety.
About MolecularMD
MolecularMD Corporation develops and commercializes specialty molecular
diagnostics for oncology applications. Tests are designed to allow
appropriate selection, monitoring and management of patients treated
with molecularly-targeted cancer therapies. MolecularMD integrates
gold-standard and innovative platform technologies with clinical assay
design, validation and centralized testing to accelerate all phases of
clinical development, including FDA approval and commercialization of in
vitro companion diagnostic tests for novel anticancer agents.
Contacts
Recent CDMO News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 09/09/2024 08:43:56 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/09/2024 08:19:30 PM
- Avid Bioservices Reports Financial Results for First Quarter Ended July 31, 2024 • GlobeNewswire Inc. • 09/09/2024 08:05:31 PM
- U.S. Futures Rise Amid Inflation Report Anticipation; Oil Prices Climb on Hurricane Threat and Supply Concerns • IH Market News • 09/09/2024 10:09:14 AM
- Avid Bioservices to Report Financial Results for First Quarter of Fiscal Year 2025 After Market Close on September 9, 2024 • GlobeNewswire Inc. • 09/03/2024 08:05:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/29/2024 08:30:10 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 08/28/2024 08:34:04 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 08/28/2024 08:32:18 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 08/28/2024 08:30:28 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/16/2024 11:50:20 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/16/2024 11:48:19 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/15/2024 08:40:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/12/2024 08:30:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/11/2024 09:02:39 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/11/2024 09:02:27 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/11/2024 09:01:22 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/11/2024 09:01:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/11/2024 09:00:54 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/11/2024 09:00:45 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 07/11/2024 12:23:26 AM
- Avid Bioservices Reports Financial Results for Fourth Quarter and Fiscal Year Ended April 30, 2024 • GlobeNewswire Inc. • 07/02/2024 08:05:04 PM
- Avid Bioservices to Report Financial Results for Quarter and Fiscal Year Ended April 30, 2024, After Market Close on July 2, 2024 • GlobeNewswire Inc. • 07/01/2024 11:00:21 AM
- Avid Bioservices Earns Committed Badge from EcoVadis for Sustainability Performance • GlobeNewswire Inc. • 05/23/2024 12:05:46 PM
- Avid Bioservices to Participate at Upcoming Investor Conferences • GlobeNewswire Inc. • 05/07/2024 08:05:11 PM
- Avid Bioservices Reports Financial Results for Third Quarter Ended January 31, 2024 • GlobeNewswire Inc. • 04/24/2024 09:25:33 PM
FEATURED Element79 Gold Corp Announces 2024 Clover Work Plans & Nevada Portfolio Updates • Sep 10, 2024 11:00 AM
Kona Gold Beverage Inc. Reports $1.225 Million in Revenue and $133,000 Net Profit for the Quarter • KGKG • Sep 10, 2024 1:30 PM
Nightfood Holdings Inc. Completes Major Step on Uplist Journey by Closing Strategic All-Stock Acquisition of CarryoutSupplies.com • NGTF • Sep 10, 2024 8:15 AM
Element79 Gold Corp. Announces Sale of 100% Interest in Elder Creek, North Mill Creek, and Elephant Projects to 1472886 B.C. Ltd. • ELEM • Sep 9, 2024 9:34 AM
North Bay Resources Commences Gold Shipments, Fran Gold Project, British Columbia; Enters Taber Gold Mine JV, Sierra County, California • NBRI • Sep 9, 2024 9:15 AM
Simple Stock Loans Announces Unique Solutions For Investors Looking for Alternative Liquidity Amidst Recent Small Cap Rally Sep 6, 2024 9:30 AM